AI Rare Disease AI Specialist Interview Questions

Should mention low patient numbers, heterogeneous symptoms, and the resulting scarcity of structured, labeled data for model training.

Should mention OMIM, ClinVar, Orphanet, gnomAD, or UK Biobank and explain what data they hold (e.g., gene-disease links, variant frequencies).

Should explain a graph structure of nodes and edges and how it can link genes, proteins, phenotypes, drugs, and publications from siloed sources.

Should describe using a model pre-trained on a large dataset (like general text or genomics) and fine-tuning it on the small rare disease dataset to boost performance.

Should mention privacy, informed consent, data de-identification, potential for bias against underrepresented populations, and the risk of false hope from model predictions.

Should discuss strategies like using pre-trained embeddings, data augmentation (if possible), one-class classification, leveraging related disease data, and focusing on interpretability.

Should outline steps: checking frequency (gnomAD), computational predictions (CADD, REVEL, AlphaMissense), conservation, and literature/NLP mining. Should mention tools like Ensembl VEP.

Should mention steps like de-identification, tokenization, named entity recognition (for symptoms), negation detection, and normalization to ontologies like HPO. Should reference tools like scispaCy or medSpaCy.

Should define both, note PRS aggregates many variants for common diseases, and caution that most rare diseases are monogenic/mendelian, making traditional PRS less relevant but potentially useful for modifier genes.

Should mention rigorous validation on hold-out data, literature-based mechanistic plausibility checks, assessing model uncertainty/limitations, and suggesting specific *in-vitro* or *in-vivo* experiments for validation.

Should define learning from very few examples. Should mention models like Siamese Networks, Matching Networks, or Transformers with attention mechanisms designed for few-shot tasks.

Should discuss data normalization, separate feature extraction models, and fusion strategies (early, late, or hybrid fusion) to combine modalities into a unified representation.

Should explain class imbalance (high accuracy by always predicting 'not rare'). Should recommend metrics like AUPRC (Area Under Precision-Recall Curve), F1-score, or clinical utility measures.

Should explain a computational model of an individual's biology for simulation. Would need multi-omics, clinical history, and potentially pharmacokinetic data.

Should outline a RAG (Retrieval-Augmented Generation) pipeline with PubMed API integration, embedding of abstracts, a vector database, and a prompt engineering strategy to generate summaries with citations.

Should mention challenges in AAV capsid design (using generative models like diffusion models), predicting off-target edits (using models like CRISPR-ML), and predicting tissue-specific expression (sequence-based deep learning models).

Should explain the central server/aggregator, local model training on site, and communication of model weight updates (not data). Should discuss challenges of data heterogeneity (non-IID data) across sites.

Should note strengths: knowledge synthesis, few-shot prompting. Failure modes: hallucinations of rare facts, bias towards common diseases, lack of grounding in patient-specific data. Guardrails: RAG to a curated knowledge base, strict output formatting, mandatory human-in-the-loop verification.

Should describe using genetic variants as instrumental variables to infer causal relationships between modifiable risk factors and disease. Then using AI/ML to integrate this causal graph with other data (PPI networks, drug databases) to rank targets.

Should explain false discovery rate inflation. Should discuss methods like Bonferroni correction (conservative), Benjamini-Hochberg FDR control, or more advanced Bayesian approaches for structured hypotheses.

Should discuss validation on diverse populations, monitoring for model drift post-deployment, continuous learning concerns, and the need for a predetermined change control plan. TPLC is the FDA's framework for regulating AI/ML that learns over time.

Should discuss framing treatment as a sequential decision problem. Mention using model-based RL to simulate patient trajectories from observational data, or off-policy RL methods to learn from suboptimal historical treatment policies.

Should outline a multi-pronged approach: 1) Use NLP to mine literature for gene function and related phenotypes. 2) Run multiple *in-silico* pathogenicity predictors (e.g., AlphaMissense, SpliceAI). 3) Query patient-matching databases (like Matchmaker Exchange) via API. 4) Check protein structure prediction (AlphaFold) for impact of the variant.

Should discuss integrating heterogeneous data (phenotypes via HPO terms, genomics, MRI features). Recommend using an embedding model (like a variational autoencoder) to create a latent patient representation, then building a graph based on similarity in that space. Highlight the need for patient privacy.

Should describe: 1) Double-checking data and model for leaks/errors. 2) Performing *in-silico* biological plausibility analysis (pathways, expression). 3) Designing a minimal *in-vitro* experiment (e.g., if a cell phenotype is predicted). 4) Writing a concise report with clear limitations and suggesting collaborative validation.

Should propose a phased approach: 1) Define a common data model (e.g., OMOP CDM). 2) Use NLP/HE tools to extract and map key data elements locally at each site. 3) Consider federated learning or a secure multi-party computation framework if direct data pooling is impossible. 4) Acknowledge the immense resource and trust-building required.

Should evaluate: 1) Mechanistic plausibility (does the drug target the same pathway?). 2) Known side effects and blood-brain barrier penetration. 3) Potential for seizure-inducing properties (a known risk with some antidepressants). 4) Look for any anecdotal reports in literature or patient forums. Stress that this is a hypothesis-generating tool, not a prescription.

Should describe a process: 1) Topic modeling (LDA, BERTopic) to identify key themes. 2) Sentiment analysis to gauge impact. 3) Named entity extraction (symptoms, treatments, side effects) using a biomedical NER model. 4) Manual curation with patient advocates to create a validated feature set (e.g., 'reported nocturnal seizures').

Should suggest techniques: 1) Use SHAP or LIME to explain individual predictions (which features contributed most). 2) Create a distilled, simpler model (e.g., a decision tree) that approximates the complex one for rule-based understanding. 3) Develop visualizations linking genetic features to biological pathways.

Should discuss: 1) Identifying and quantifying the bias. 2) Actively seeking and incorporating diverse datasets (e.g., from H3Africa, All of Us). 3) Using techniques like adversarial debiasing or fairness-aware constraints during training. 4) Clearly reporting model performance disparities across subgroups.

Should cover steps: 1) Data cleaning and de-identification. 2) Tokenization and creation of a HuggingFace `Dataset`. 3) Setting up training arguments (learning rate, epochs). 4) Using `Trainer` API. 5) Evaluation strategy (perplexity, downstream task). 6) Saving and sharing the model via the Hub.

Should mention: 1) Using Docker or Singularity for containerization. 2) Version controlling code (Git) and data (DVC or cloud storage versioning). 3) Using an experiment tracking tool like MLflow or Weights & Biases. 4) Defining infrastructure as code (e.g., AWS CDK/Terraform) for cloud resources (S3, SageMaker).

Should outline: 1) Loading/scraping OMIM text. 2) Splitting documents into chunks. 3) Creating embeddings with a model like `text-embedding-ada-002`. 4) Storing vectors in a database (e.g., FAISS, Chroma). 5) Setting up a LangChain chain that retrieves relevant chunks and passes them as context to an LLM for question answering.

Should discuss using workflow managers like Nextflow or Snakemake, containerized tools, parallel processing on cloud instances (e.g., AWS Batch), and cost-optimization by using spot instances and appropriate storage tiers (S3).

Should mention: 1) Setting up alerts for data drift (changes in variant frequency distribution). 2) Tracking prediction confidence scores. 3) Logging clinician feedback/overrides. 4) Periodically re-evaluating on a curated, evolving gold-standard set of variants. 5) Using tools like Evidently AI or NannyML.

Should describe an automated pipeline: 1) Scheduled scraping of PubMed/ORPHANET via APIs. 2) Use of NLP to extract new relationships. 3) Validation rules before ingestion. 4) Versioning the graph (using Neo4j's built-in features or a Git-like approach for RDF). 5) Linking graph versions to specific model versions for reproducibility.

Should discuss strategies to avoid overfitting: 1) Using univariate statistical tests (ANOVA, mutual information) to filter top features. 2) Using regularization (Lasso) within a cross-validated loop. 3) Applying dimensionality reduction (PCA) before modeling. 4) Emphasizing the importance of a nested cross-validation scheme.

Should focus on clinical utility: 1) A summary panel with key diagnosis candidates and confidence. 2) An interactive view linking variants to genes and known phenotypes (from HPO). 3) A 'clinical action' panel suggesting next steps (e.g., 'Consider testing for X'). 4) Clear disclaimers and a feedback mechanism.

Should demonstrate strong communication, use of analogies, focus on impact rather than technical details, and active listening to confirm understanding.

Should show resilience, intellectual humility, scientific rigor in validation, and the ability to pivot. Should highlight what the 'failure' taught about the data or biology.

Should discuss frameworks for evaluating urgency vs. importance, clear communication of timelines and trade-offs, and sometimes advocating for sustainable development practices over constant 'fire-fighting'.

Should emphasize respect for domain expertise, curiosity to understand the expert's reasoning, joint deep-diving into the data, and finding a compromise that advances scientific truth.

Should reflect on the human impact, commitment to data privacy and de-identification, focusing on verifiable evidence over anecdote, and the responsibility that comes with handling such data.